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EDITORIAL COMMENT
Introduction
Renal disease and hypertension in pregnancy re-
main a major cause of morbidity and mortality in
both mother and fetus. Research in this important
area of reproductive medicine has been dis-
organized and sporadic, which is surprising because
the kidney has been part of the "toxemia" story,
and obstetricians have examined gravidas' urine
samples for abnormal protein excretion for over a
century! We thus hope that this symposium will be
not only a "review of the art," but also a call to
action that will stimulate active interest in the field.
The symposium has been divided into three broad
categories: renal physiology, renal disease, and the
hypertensive disorders of gestation. In the first ar-
ticle, Drs. Davison and Dunlop review hemo-
dynamics and tubular function in normal human
pregnancy. These two academic obstetricians have
availed themselves of their excellent rapport with
their patients and community to perform imagina-
tive and outstanding clinical investigations. For ex-
ample, they have recruited volunteers who wish to
conceive and, by collecting blood and urine samples
weekly, have carefully determined how soon after
the missed menstrual period the normal gravida ex-
periences physiologic increments in creatinine
clearance and glucose excretion. In this cooperative
population, they have also performed serial infusion
studies starting prepartum and ending after the
puerperium to investigate glomerular function and
renal glucose and urate handling during pregnancy.
Some of Davison and Dunlop's conclusions vary
with those in the literature, and should thus stimu-
late further research. They confirm that renal hemo-
dynamics (measured as inulin and PAH clearances)
increase about 50% during gestation and demon-
strate that endogenous creatinine clearance rises
early in the first trimester. They revive an older no-
tion, however, that GFR or at least the 24-hour
creatinine clearance decreases during the last gesta-
tional month [1]. This change must be taken into
account in the clinical scrutiny of high-risk preg-
nancy. Their observation that serum urate rises as
its clearance decreases in normal late pregnancy is
also controversial, because some regard any in-
crements in urate concentrations as an early sign of
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preeclampsia, which antedates changes in glomeru-
lar filtration and clinical signs of the disease [2].
Davison and Dunlop also suggest that the filtra-
tion fraction decreases during most of gestation,
whereas the opposite notion seems established in
the literature [3, 4]. They are, however, appropri-
ately circumspect in their conclusions, being aware
of the many methodologic pitfalls that have plagued
investigators studying renal function during preg-
nancy. For instance, infusion of sustaining solu-
tions at rates that were calculated to keep urine flow
high during acute testing (to obviate the dead space
problem due to physiologic dilatation of the ureters in
pregnancy) may have resulted in some studies in
subtle volume expansion of the women tested, and
consequently in substantial increments in renal
plasma flow compared with GFR. Resolution of the
fate of filtration fraction during pregnancy is of in-
terest in analyzing factors responsible for the in-
crease in GFR and determinants of renal salt han-
dling during gestation.
Definition of "normal" volume homeostasis dur-
ing pregnancy is another controversial topic. Until
recently, salt was considered dangerous, and preg-
nant women were requested to shun it, were
warned against abnormal" weight gain1, and even
were given "prophylactic" diuretics. Lately, gravi-
das have been considered subtle sodium wasters,
and supplemental salt has been advocated as a
means of avoiding preeclampsia [5]. Most recently,
a third view has been published that suggests that
renal sodium handling is identical in pregnant and
nongravid women [6]. The general topic of sodium
and mineralocorticoids in normal gestation is re-
'Mean weight gain in pregnancy is about 12 kg/gestation. Of in-
terest is how often practitioners tend to regard published averages
as upper limits of permissible weight gain, neglecting that there is
a plus as well as a minus to the deviation about a mean. Thus, too
many gravidas have been admonished in the past for excessive
weight gain, and their salt or calories were needlessly restricted.
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viewed by Drs. Nolten and Ehrlich. They take the
view that despite marked increments in plasma and
interstitial volume during pregnancy, the gravida
does not act "physiologically" as if she were vol-
ume expanded. In essence, her volume receptors
sense such substantial increments in the intra-
vascular and interstitial spaces as if they were at the
lower limits of normal, and when salt restriction or
diuretic therapy limits this physiologic hyper-
volemia, the maternal response is similar to that of
salt-depleted nongravid subjects.
A normal gravida experiences a cumulative reten-
tion of some 900 mEq of sodium during an average
gestation. As Nolten and Ehrlich note, this takes
place over a period of 9 months, so that even when
accumulation is greatest the daily positive balance
is only 4 to 5 mEq of sodium, and gravidas excrete
virtually all of the ingested salt. This is why it has
been difficult to demonstrate subtle salt retention or
wasting during conventional balance studies. When
third trimester gravidas are salt restricted, how-
ever, especially to 10 mEq or less of sodium per
day, fetal requirements should make the pregnant
woman resemble a patient that is cirrhotic and vir-
tually eliminate sodium from her urine. In this re-
spect, a recent study by Bay and Ferris [6] is of in-
terest. Gravidas were salt restricted for 7 days,
failed to gain the usual 1 to 2 lbs of weight normally
expected each week in late gestation, and actually
lost an average of 1 kg during the test period. They
were unable to abolish urinary sodium excretion
and, in fact, excreted an equal or higher amount of
sodium that did the nonpregnant controls despite
fourfold elevations in renin and aldosterone levels.
These observations adduce some of the most potent
evidence to date that normal gravidas are unable to
cope with rigid salt restriction.
Nolten and Ehrlich focus further on the possible
importance of desoxycorticosterone (DOC), a corti-
coid barely investigated in pregnant women.
Whereas aldosterone secretion, which is markedly
increased during gestation, responds appropriately
to physiologic maneuvers, maternal DOC concen-
trations (which probably derive from a fetal source
at a fixed rate) remain substantially elevated even
after gravidas have undergone considerable volume
expansion. These "fixed" levels of DOC in the
third-trimester woman may play a role in the abnor-
mal salt retention that accompanies preeclampsia.
The review by Nolten and Ehrlich concludes with
remarks about diuretic therapy during gestation.
They find little use for these agents in pregnancy,
similar to conclusions voiced by us some years ago
[7].
The first section of this symposium focuses on
unsolved problems concerning renal hemodynamics
and volume homeostasis during normal gestation.
Are there good animal models susceptible to a more
detailed analysis of these questions? Drs. Alexan-
der, Churchill, and Bengele, among the first to ex-
plore renal function in pregnancy with micro-
puncture techniques, review renal hemodynamics
and sodium balance in pregnant Sprague Daw-
ley rats and identify aspects of gestation in this
species that resemble human pregnancy. GFR does
increase in the rat, but apparently only near term.
Renal plasma flow does not, and therefore filtration
fraction rises. There is also a maternal physiologic
hypervolemia because both plasma volume and in-
ulin spaces increase in the dam.
One point not discussed by Alexander et al but of
interest to us relates to the conflicting opinions on
whether the functional hypertrophy seen during
pregnancy in the rat is accompanied by kidney
growth, in a sense akin to compensatory renal hy-
pertrophy after uninephrectomy. This question has
been studied recently by Davison and Lindheimer
[81, who compared dry kidney weight and the incor-
poration of 14C-choline in membrane phospholipids
of cortical slices in gravid rats and their virgin litter-
mates. Using these two sensitive indices, they
found no evidence of renal growth.
The second section of this symposium is devoted
to renal disease. Drs. Grünfeld, Ganeval, and Bour-
nerias review acute renal failure in pregnancy, ana-
lyzing the experience of Hôpital Necker, Paris (a
referral center), between 1957 and 1979. Their dis-
cussion includes two poorly understood syn-
dromes, one associated with acute fatty liver of
pregnancy and the other, first described in the late
1960's, termed idiopathic postpartum acute renal
failure.
Classically, the incidence of acute renal failure in
pregnancy is bimodal, with peaks occurring early in
gestation and again near term. The first is due pri-
marily to sepsis and seems to be declining in coun-
tries with liberal abortion laws, and the peak near
term is related to preeclampsia, abruption, and
bleeding problems such as placenta previa. Of fur-
ther interest is the increased propensity of gravidas
compared with other populations to develop that
dreaded cause of renal failure, cortical necrosis.
Several years ago [9], the Necker group demon-
strated two interesting facts: One, cortical necrosis
early in gestation has a frequency similar to that in
the population at large, and it is only in the group
that develops renal failure near term that the in-
cidence increases. Second, most cases of cortical
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necrosis are associated with abruption, and the le-
sion is often of the "patchy" variety. This entity is
characterized by an initial episode of severe oh-
guria, followed by a variable return of function and
a stable period of moderate renal insufficiency.
Years later, however, renal function decreases
again for obscure reasons, often leading to end-
stage renal disease.
In the past, the coexistence of pregnancy and pa-
renchymal renal disease, regardless of type or se-
verity, alarmed physicians who inclined to termi-
nate the gestation and to recommend strict con-
traception thereafter. More recently, it has become
apparent that many such gestations, when carefully
managed, can be successfully completed, especially
if renal dysfunction is mild and hypertension ab-
sent.
In an attempt to gain a better perspective on the
relationship between renal disease and pregnancy,
we have organized a collaborative venture between
the Universities of Newcastle-upon-Tyne, Yale,
and our own institution. All the women included in
this survey were diagnosed by renal biopsy, a factor
missing from most of the published literature. Be-
cause systemic lupus erythematosus is probably the
disease with the most disputed natural history in
gestation, a mail survey of centers was organized by
Drs. Hayslett and Lynn, whose results are dis-
cussed separately.
We wish to emphasize that patients derived pri-
marily from nephrology centers create a highly se-
lected population. Consultants usually see the most
complicated cases, but those of us based in prenatal
clinics are aware of occasional women with mild renal
dysfunction who escape the nephrologist's needle;
in fact, their disease initially may be detected be-
cause the obstetrician is the most loyal user of the
urinalysis. The majority of such pregnancies do
well. Although the patients analyzed by Katz, Hay-
slett, and their respective colleagues experienced a
number of complications during pregnancy, most
gestations were nonetheless successful, and there
was no evidence of an adverse effect of pregnancy
itself on the natural history of the renal disease.
The second section concludes with a discussion
of pregnancy in women with transplanted kidneys
by Drs. Penn, Makowski, and Harris, who rely on a
decade of rich experience in this area. They note
that even though most of these gestations succeed,
these are truly high-risk pregnancies, which require
certain precautions and close supervision. By 1980,
hundreds of women with kidneys from both live and
cadaver donors will have conceived, and the num-
ber will certainly increase in the next decade. Per-
haps now is the time to provide published guidelines
concerning advice to such women when they wish
to become pregnant.
We recently perused reports from the literature
on 75 transplant recipients who had achieved 90
pregnancies (including two sets of twins) [10]. It
was evident that many such women were poorly
counselled before conception and had inadequate
antenatal care. One third of the patients received no
prior advice about contraception, and many of them
were under the impression that they could not con-
ceive. Pregnancy was not diagnosed until well into
the second trimester in 24 instances, and on one oc-
casion, almost at term. The message of these obser-
vations should be clear!
The final section is devoted to the hypertensive
disorders of pregnancy, perhaps the most con-
troversial segment in this symposium. Chamberlain
et al [11], as well as Lewis and Zuspan (Zuspan FP,
personal communication), have performed mail sur-
veys, attempting to determine how physicians cur-
rently manage hypertension in pregnancy. Results
of these studies are quite revealing. Treatment of
preeclampsia, especially when convulsions occur or
seem imminent in the patient, is markedly different
in England from the practices currently used by
American obstetricians. Furthermore, in the United
States, 86% of the academic obstetricians surveyed
would not use diazoxide to treat women who sud-
denly manifest moderate or severe hypertension at
term, but over 50% of the surveyed nephrologists
would! These discrepancies underscore several
facts: We have much to learn about the patho-
physiology of high blood pressure during gestation,
especially during preeclampsia. Second, many
current treatment regimens have not been validated
by controlled trials. Furthermore, many physicians
not cognizant of certain functional changes specific
for preeclampsia prescribe therapy that, although
appropriate in nonpregnant populations, may be un-
wise in gravidas.
In the first article of this section, Dr. Chesley de-
fines hypertension in pregnancy and discusses fa-
milial factors and remote prognosis, focusing on
preeclampsia. The seemingly simple process of
classifying the hypertension disorders of gestation
has been an important reason for much of the con-
fusion in the literature. This is also evident in the
current symposium, for even though Dr. Chesly re-
views the recommendations of the American Col-
lege of Obstetricians' Committee on Terminology,
subsequent contributors introduce different terms.
Some of the difficulty concerning the classification
of hypertension during pregnancy arose because it
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Table 1. Renal pathology in 176 hypertensive patientsa
Diagnosis
No. of
patients Primigravidas Multiparas
Preec1ampsia'
With nephrosclerosis
With renal disease
With both
96
13
3
2
79
6
1
1
17
7
2
1
Nephrosclerosis
With renal disease
19
4
3
2
16
2
Renaldisease 31 12 19
Normal histology 8 0 8
a In this survey, biopsy material obtained between 1958 and
1976 was reviewed. Material was considered adequate if it con-
tained 8 glomeruli for light and 3 for electron microscopic analy-
sis, respectively [12].b Only glomerular endotheliosis on biopsy
is often impossible to distinguish on clinical grounds
between preeclampsia, essential hypertension, high
blood pressure secondary to kidney disease, and
combinations of these entities. This point is illus-
trated in a clinicopathologic correlative study per-
formed at The University of Chicago [12]. Table 1
demonstrates the pathologic diagnosis of 176 gravi-
das biopsied postpartum at Chicago Lying-in Hos-
pital between 1958 (introduction of electron micros-
copy at that institution) and 1976. All these preg-
nancies were complicated by hypertension, and in
most of the cases the clinical impression was that
the patient had preeclampsia. This diagnosis was
most often incorrect in multigravidas (but also in
25% of the primigravidas). There was a surprisingly
large number of patients with unsuspected renal dis-
ease. These data illustrate the problems of inter-
preting reports in which the diagnosis is based sole-
ly on clinical grounds, especially where many of the
women classified as preeclamptic are multiparous.
In the absence of kidney biopsy, eclampsia (a
convulsion) is highly suggestive that the gravida had
true preeclampsia. Dr. Chesley's systematic exami-
nation of 270 such women, with only a few lost to
followup, stands out as an epidemiologic tour de
force with few equals. His data have added impor-
tant knowledge on the remote cardiovascular prog-
nosis of preeclamptic women, and his suggestion
that the propensity for this disease may be inherited
as an autosomal recessive trait is quite intriguing.
Professor Sheehan, still active entering his ninth
decade, discusses renal morphology in preeclampsia.
Much of this work owes its excellence to his in-
sistence on being aware of the clinical situation long
before a patient's demise, which enabled him to
perform most of the autopsies in his hospital within
15 mm to 2 hours after death. His contribution in
this symposium compares such fresh autopsy mate-
rial to that derived from renal biopsy (the latter
usually obtained postpartum and in a reparative
stage of the disease).
The article by Dr. Gant et al reviews factors that
control vascular responsiveness in human preg-
nancy. This group has performed serial angiotensin
infusion tests during gestation and has demon-
strated that altered vascular reactivity (as demon-
strated by a loss of the resistance that gravidas nor-
mally display to this pressor peptide) is the earliest
sign of future preeclampsia. These changes occur
long before clinical signs or symptoms of the dis-
ease, such as hypertension, proteinuria, edema, or
evidence of coagulopathy. Gant et al continue to ana-
lyze the determinants of vascular reactivity during
gestation, which are aptly described in their article.
The final contributions are devoted to the man-
agement of hypertension complicating gestation.
The reader will quickly ascertain some striking dif-
ferences in the approach of each author to the hy-
pertensive emergencies in pregnancy: Dr. Prit-
chard, who successfully managed 154 consecutive
eclamptics without a maternal death, describes the
therapeutic regimen used at the Parkiand Memorial
Hospital in Dallas. We quote one of his comments:
The protocol for management of eclampsia and se-
vere preeclampsia used for more than two decades
has proven highly effective and safe. Al-
though this protocol has been faulted for empiri-
cism, it has not been faulted for achievement."
Dr. Redman is an internist who oversees a refer-
ral clinic attended by gravid hypertensives at the
Radcliffe Infirmary at Oxford. His contributions in-
clude one of the few controlled studies on anti-
hypertensive medications in the management of
high blood pressure during gestation.
These last two articles allude to the major current
controversy concerning treatment of the hyperten-
sive disorders of gestation. Data from morphologic
studies of placentae demonstrate trophoblastic in-
vasion of the muscular coats that surround the uter-
ine spiral arteries, and observations in unanesthe-
tized sheep or primates suggest that the uterine ar-
teries behave like rigid conduits, or are normally in
a maximally dilated state (literature reviewed in
Refs. 3 and 4). Thus, some investigators believe
that reductions in maternal blood pressure decrease
uteroplacental perfusion and caution against large
decrements in mean arterial pressure, especially in
acute emergencies (placental perfusion is already
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compromised in preeclampsia). In contrast, others
working primarily with anesthetized rabbits report
that there is complete autoregulation of uterine
blood flow over a wide range of pressures in the
dam, and, on this basis, they recommend aggressive
lowering of blood pressure when hypertension com-
plicates human gestation. Data from human preg-
nancy are indirect and limited, but they suggest that
acute reductions in maternal pressure may reduce
uteroplacental perfusion. A critical but unanswered
question, assuming that autoregulation does exist,
is how quickly it occurs, for the fetus will be com-
promised if ischemia persists. There are already
documented instances where precipitous reductions
of blood pressure after diazoxide (even when dia-
stolic levels still exceeded 85 mm Hg) were accom-
panied by signs of fetal distress [13]. Until these
controversies are resolved, an intermediate ap-
proach is justified, in which antihypertensive drugs
are not prescribed during pregnancy as long as ma-
ternal blood pressure is only mildly or moderately
elevated. In hypertensive emergencies, we recom-
mend the gentle use of parenteral hydralazine only
when blood pressure exceeds a diastolic level of 105
mm Hg. The decrement in diastolic pressure is best
limited to achieve levels betweeen 95 and 100 mm
Hg, and the treatment should include close mater-
nal scrutiny combined with fetal monitoring. Each
case must be considered individually; some women
with low blood pressure early in gestation (for ex-
ample, teenage gravidas with diastolic measure-
ments of 50 mm Hg) should be treated earlier and
their diastolic pressures reduced to values below
those cited above.
In conclusion, this symposium reviews current
knowledge of kidney function and disease in preg-
nancy and highlights several areas of controversy.
Throughout the editorial, we espoused our own
views liberally, and we hope not too dogmatically,
while emphasizing that there is a paucity of investi-
gative data behind many of the conflicting argu-
ments. We anticipate that the next symposium in
Kidney International devoted to these topics will
provide much of the information required to sup-
port or refute the opinions expressed in this editori-
al.
MARSHALL D. LINDHEIMER
ADRIAN I. KATZ
Chicago
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